

## Coronavirus: what now for economies and markets?

It's been a tumultuous time for investors everywhere. Momentum is the key when looking at future prospects for stock markets and employment prospects across the continent

**Paul Doyle**, Head of Europe ex-UK Equities



Europe is now more than half a year into the coronavirus pandemic, having spent the first quarter of 2020 watching helplessly as the

disease swept across China and the east. As the outbreak arrived here we saw border closures and travel restrictions, enforced working from home and limits on social contact. As elsewhere, European economies took a pounding.

So, how have markets reacted? Leadership was at first defensive, led by technology and pharmaceuticals, and this persisted until value stocks hit their nadir on 18 May.<sup>1</sup> June saw the market rebound broaden. Price/earnings ratios of banks and "value cyclicals" had hit rock-bottom, which was not sustainable.

Up to the end of April, many active managers outperformed the index because they were defensively positioned, and in this phase there was no apparent disconnect: investors were cautious and data was bad. But more recently equity markets have decoupled from fundamental economics, particularly in the US.

Cyclical stocks were terrible performers until mid-May but then bounced back: in a month the banks sub-index recovered by 30%. Food and beverages, which earlier benefited from being in the defensive camp, became the worst performing sector and mining



and financials the best. In that period, value-oriented stocks unwound most of the losses and year-to-date returns turned positive. Asian markets were the most extreme movers, as relative performance of these stocks completely reversed.<sup>2</sup>

Some see this as more than tactical, but we are not so sure. The correlation of value-versus-growth with other factors can be ranked: firstly with bond yields, then PMI momentum (purchasing managers index, a measure of economic trends), then with the US dollar, then the oil price. For a rotation to last it needs help from these factors, yet the main job of the US Federal Reserve now is to keep bond yields under control.

So, the rotation is stalling because bond yields have stalled. And while PMI momentum suggests a V-shaped recovery, as does recent market performance, we are still 20% behind the old norms,<sup>3</sup> so we are also seeing the second factor: activity momentum rolling over.

### Losing momentum

In January, before the Covid-19 crisis, the first phase of the US-China trade deal was signed and Phase Two was imminent. It seemed President Trump and China were playing ball and that Trump was a dead-cert for a second term. Then the crisis hit and economic data collapsed. The last month has seen an uptick, but that trend is not going to accelerate from here. US retail

► sales for May were up 17% year-on-year, a huge rebound – but they had fallen 15% in April. Weekly same-store sales growth has since turned down again.<sup>4</sup>

Figure 1 shows the New York Fed weekly economic index rolling over. So the economic surprise index seems to have peaked and may deteriorate from here. The PMI fell to 20 before bouncing back to 50, but it is probably too late to hope for further outperformance from financials and cyclical.

**Figure 1: US Federal reserve bank of New York weekly economic index**



Source: Bloomberg/Federal Reserve Bank of New York, July 2020.

True, demand is pent-up – for example, it was simply impossible to buy any car or a property in the middle of shutdown and now we are playing catch-up – and will bounce, but crucially it will lack sustainable momentum. Chinese car sales, for example, recently showed a fall of 17% over four weeks and are now back to March's levels.<sup>5</sup> They were helped by central bank and fiscal support, but to believe this trend continues would imply higher bond yields and an (unlikely) acceleration in the growth rebound.

### Employment fallout

The market is currently discounting a V-shaped recovery, but we believe job losses endanger this. As economies reopen, jobs data will get worse. Higher unemployment will damage sectors that rely on crowds – leisure, hospitality and retail – as they will have a reduced capacity. The hit to the global economy will be at least 10% as we emerge from the crisis – the IMF estimates \$10 trillion will be cut from an \$85 trillion global economy.<sup>6</sup> All this is a real danger for service-oriented economies like the UK, as well as of course the US.

So, with 10% of GDP lost and the labour market impaired, there is no chance of 2% inflation, so the 10-year yield will be nailed to zero. PMI data, meanwhile, shows China was first in and out of this downturn. In March, when the Chinese PMI rallied from 30 to 50, bank shares rose 35%, but they are now back to their relative lows.<sup>7</sup> In 2009, money supply growth accelerated and cyclical bounced hard; the same happened in 2016. But Chinese money supply now is telling us we cannot rely on cyclical performing from here.


So, if bond yields and PMIs cannot rise, and Chinese money supply is stagnating, thus hampering value and cyclical stocks, what stocks will benefit?

The corollary of damaged cyclical sectors is that we can expect resumed outperformance from technology and pharmaceuticals. With inflation and interest rates nailed to the floor, it is hard to argue against defensive growth stocks. Depressed bond yields compress the discount rate, favouring long-duration assets with high and sustainable cashflows. The PE relative of European consumer staples is at a 10-year low,<sup>8</sup> and the same argument holds good for utilities, technology, healthcare and other long-duration assets.

### Looking ahead

One of the side-effects of the collapse in interest rates is that governments are incentivised to borrow just as economies most need support. Figure 2 shows a far higher fiscal response to the coronavirus than in the global financial crisis of 2008/09. With this mixture of low interest rates and massive fiscal easing, it is no surprise that equities have bounced so hard.

**Figure 2: Fiscal stimulus is greater today than it was during the GFC**



Source: BCA Research, July 2020.

“ We expect resumed outperformance from tech and pharmaceuticals. With inflation and interest rates nailed to the floor, it is hard to argue against defensive growth stocks

If Joe Biden wins the presidential election, a potential reversal of the Trump tax cuts might cut S&P 500 earnings. However, domestic change is hard to achieve in the US – just look at Trump's failed repeal of Obamacare – so under Biden the tax cuts may only be partially reversed. What does this mean for the dollar? The Fed balance sheet versus that of the rest of the world correlates with the dollar, so a burgeoning balance sheet and weakening dollar pose risks to trade. Has the dollar been going down because of the Fed's credit impulse or because of deflation? It's hard to say.

If earnings take five years to recover to the pre-virus trend, the present value of equities should be lower. But interest rates have been slashed everywhere and 10-year and 30-year yields crushed. A lower discount rate suggests *higher* not lower equities.

<sup>1</sup> Bloomberg, June 2020.

<sup>2</sup> Columbia Threadneedle analysis/Bloomberg Stoxx 600 Sector, 15 May-8 June 2020.

<sup>3</sup> Bloomberg data/Columbia Threadneedle Investments analysis.

<sup>4</sup> Johnson Redbook Index, June 2020.

<sup>5</sup> Wish research data, June 2020.

<sup>6</sup> IMF, The Global Economic Reset—Promoting a More Inclusive Recovery, 11 June 2020.

<sup>7</sup> Bloomberg, July 2020.

<sup>8</sup> Columbia Threadneedle analysis/Bloomberg, July 2020.

To find out more visit  
**COLUMBIATHREADNEEDLE.COM**



**Important Information: For use by Professional and/or Qualified Investors only (not to be used with or passed on to retail clients).** This document is intended for informational purposes only and should not be considered representative of any particular investment. This should not be considered an offer or solicitation to buy or sell any securities or other financial instruments, or to provide investment advice or services. **Investing involves risk including the risk of loss of principal. Your capital is at risk.** Market risk may affect a single issuer, sector of the economy, industry or the market as a whole. The value of investments is not guaranteed, and therefore an investor may not get back the amount invested. **International investing** involves certain risks and volatility due to potential political, economic or currency fluctuations and different financial and accounting standards. **The securities included herein are for illustrative purposes only, subject to change and should not be construed as a recommendation to buy or sell. Securities discussed may or may not prove profitable.** The views expressed are as of the date given, may change as market or other conditions change and may differ from views expressed by other Columbia Threadneedle Investments (Columbia Threadneedle) associates or affiliates. Actual investments or investment decisions made by Columbia Threadneedle and its affiliates, whether for its own account or on behalf of clients, may not necessarily reflect the views expressed. This information is not intended to provide investment advice and does not take into consideration individual investor circumstances. Investment decisions should always be made based on an investor's specific financial needs, objectives, goals, time horizon and risk tolerance. Asset classes described may not be suitable for all investors. **Past performance does not guarantee future results, and no forecast should be considered a guarantee either.** Information and opinions provided by third parties have been obtained from sources believed to be reliable, but accuracy and completeness cannot be guaranteed. This document and its contents have not been reviewed by any regulatory authority.

**In Australia:** Issued by Threadneedle Investments Singapore (Pte.) Limited ["TIS"], ARBN 600 027 414. TIS is exempt from the requirement to hold an Australian financial services licence under the Corporations Act and relies on Class Order 03/1102 in marketing and providing financial services to Australian wholesale clients as defined in Section 761G of the Corporations Act 2001. TIS is regulated in Singapore (Registration number: 201101559W) by the Monetary Authority of Singapore under the Securities and Futures Act (Chapter 289), which differ from Australian laws.

**In Singapore:** Issued by Threadneedle Investments Singapore (Pte.) Limited, 3 Killiney Road, #07-07, Winsland House 1, Singapore 239519, which is regulated in Singapore by the Monetary Authority of Singapore under the Securities and Futures Act (Chapter 289). Registration number: 201101559W. This document has not been reviewed by the Monetary Authority of Singapore.

**In Hong Kong:** Issued by Threadneedle Portfolio Services Hong Kong Limited 天利投资管理香港有限公司. Unit 3004, Two Exchange Square, 8 Connaught Place, Hong Kong, which is licensed by the Securities and Futures Commission ("SFC") to conduct Type 1 regulated activities (CE:AQA779). Registered in Hong Kong under the ce (Chapter 622), No. 1173058.

**In EMEA:** Issued by Threadneedle Asset Management Limited. Registered in England and Wales, Registered No. 573204, Cannon Place, 78 Cannon Street, London EC4N 6AG, United Kingdom. Authorised and regulated in the UK by the Financial Conduct Authority. This document is distributed by Columbia Threadneedle Investments (ME) Limited, which is regulated by the Dubai Financial Services Authority (DFSA). For Distributors: This document is intended to provide distributors' with information about Group products and services and is not for further distribution. For Institutional Clients: The information in this document is not intended as financial advice and is only intended for persons with appropriate investment knowledge and who meet the regulatory criteria to be classified as a Professional Client or Market Counterparties and no other Person should act upon it. **Columbia Threadneedle Investments is the global brand name of the Columbia and Threadneedle group of companies.**  
**columbiathreadneedle.com**

Issued 09.20 | Valid to 03.21 | J30888 | 3235525